CRT-136 Anti-coagulant Therapy During Percutaneous Coronary Intervention: A Network Meta-analysis Of Randomized Trials  by Pasala, Tilak et al.
S18 J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 8 , N O . 2 , S U P P L S , 2 0 1 5
C
O
R
O
N
A
R
YBIFURCATION
CRT-133
Safety And Feasibility Of Everolimus-eluting Bioresorbable Vascular Scaffold In
The Treatment Of Coronary Bifurcation Lesions
Ashish Shah, William Chan, Christopher Overgaard, Douglas Ing, Vladimir Dzavik
Toronto General hospital, Toronto, ON, Canada
BACKGROUND PCI treatment of coronary bifurcation lesions (CBL) is technically
challenging. Bioresorbable vascular scaffold (BVS) provides temporary vessel scaf-
folding with drug-elution; restores normal vessel architecture and physiology upon
resorption. There are limited data on the feasibility and safety of using ABSORB BVS
(Abbott Vascular) for treatment of CBL.
METHODS A retrospective analysis of CBL treated with ABSORB-BVS at a tertiary PCI
center from Sep-12 to May-14. All PCIs were performed under OCT guidance.
RESULTS A total 41 CBL were treated in 37 patients undergoing non-urgent PCIs.
Mean age of the patients was 60 years. Radial access was used in treatment of 34 CBL.
As per ’Medina’ classiﬁcation, 25 (61%) CBL were (1,1,1), 9 (22%) were (1,1,0), 4 (10%)
were (0,1,1) and 1 (2.4%) each (1,0,1), (1,0,0) and (0,1,0). Side branch (SB) were wired in
30 (73%) CBL; treated with DES in 5 (12.2%) lesions (T-stent in 2, balloon-crush in 3)
and balloon angioplasty only in 20 (48.8%) CBL. Main vessel stenting was performed
with proximal optimization technique (POT) in 20 (48.8%) CBL. Final kissing balloon
(FKB) inﬂation was performed in 10 (24.4%). BVS used per case were 2.00.2, and
mean diameter and length were 2.90.1and 22.30.9 mm respectively. Thirty-one
lesions (76%) involved LAD/diagonal vessel.
BVS treatment of CBL was successful in 40 of 41 (98%) CBL with only 1 patient in
whom delivering the BVS was difﬁcult. Failure to wire SB occurred in 3 patients, of
whom SB ﬂow compromised in 2 patients. One patient had intra-procedural left main
stem dissection treated with a drug-eluting stent. Three (7%) had biochemical but not
clinical evidence of peri-procedural MI. Mean follow-up was of 110  15 days. One
patient died with suspected sub-acute BVS thrombosis and 1 underwent drug-eluting
balloon treatment of in-scaffold restenosis.
CONCLUSIONS
1. A wide range of CBLs can be safely and effectively treated with ABSORB BVS.
2. Intravascular imaging is mandatory to guide BVS sizing and for assessment of strut
apposition and integrity.
3. Wire crossing of BVS struts and dilating through them into the SB appears safe.
4. Sequential balloon post-dilatation and FKB inﬂation appear safe and feasible.CABG
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Screening Carotid Ultrasound in Patients Undergoing Cardiac Surgery: Does
Severity of Carotid Stenosis Predict Post-Operative Cerebrovascular Accidents?
Lucas Christianson, Anhilkumara Mehra, Khuyen Do, Blake Brown
USC, Los Angeles, CA
BACKGROUND Guidelines recommend that high-risk patients be screened for carotid
artery disease prior to cardiac surgery. High-risk patients are deﬁned as those with
age >65 years, left main disease, peripheral arterial disease, history of cerebrovas-
cular disease (TIA or stroke), hypertension, smoking or diabetes.
OBJECTIVES Identify the incidence of carotid artery disease and outcomes of cardiac
surgery. Endpoints include mortality, cerebrovascular accident, and prevalence of
signiﬁcant carotid stenosis (80-99%) and prevalence of carotid endarterectomy.
METHODS A retrospective analysis of LACþUSC Medical Center and Keck Medical
Center coronary artery bypass patients from January 2012 to December 2013 was
performed.
RESULTS We identiﬁed 340 patients (78% female, 22% male); average age was 61
years. The majority of the patients underwent pre-operative carotid screening with
ultrasound (93%). Signiﬁcant carotid artery stenosis (80-99%) was found in 41 ar-
teries, which accounted for 12% of patients. Of the patients with signiﬁcant carotid
artery stenosis 8 (2.35%) underwent carotid endarterectomy (two of the patients
underwent endarterectomy post-bypass). There were 3 post-operative cerebrovas-
cular events (0.88%). Overall mortality was 1.18%.
CONCLUSION The incidence of signiﬁcant carotid stenosis is low and even lower for
those requiring pre-operative intervention of the carotid stenosis. The overall mor-
tality and incidence of cerebrovascular events are also low. Of the three patients with
post-operative cerebrovascular events, none had signiﬁcant carotid stenosis. Further
research will investigate risk factors to identify a higher risk population that may
derive beneﬁt from pre-operative screening.CRT-135
Off-pump Coronary Artery Bypass Grafting Is Associated With Higher Rate Of
Percutaneous Coronary Intervention At 8-year Follow-up. Results From The
Priority Study
Fulvia Seccareccia,1 Paola D’Errigo,1 Fabio Barili,2 Stefano Rosato,1 Lorenzo Menicanti3
1National Health Institute, Rome, Italy; 2Department of Cardiac Surgery, S. Croce
Hospital, Cuneo, Italy; 3IRCCS Policlinico San Donato, San Donato Milanese (Milan),
Italy
BACKGROUND The debate on the advantages and limitations of off-pump (OP) vs on
pump (ON) CABG has not still arrived to a conclusion and concerns still exist on graft
patency. Aim of this study was to compare the impact of OPCABG and ONCABG on
mortality and morbidity, with a speciﬁc focus on mid-term need for percutaneous
cardiac intervention (PCI).
METHODS The PRIORITY study is designed to evaluate mid and long term outcomes
in a cohort of patients undergoing a CABG intervention in 2004 and between 2007-
2008 in some Italian Cardiac Surgery Centers. Data on isolated OP and ON CABG
interventions were derived from the study clinical dataset while follow-up infor-
mation were derived from the national registry of Hospital Discharge Records
collected in Italy from 2004 to 2012, linked with the national Tax registry. The time-
to-event distributions were compared separately according to primary event-type
(death or hospitalization for PCI), using the Cox regression for the time-to-death
analysis and the competing risk analysis for time-to-PCI, with death as competing
risk.
RESULTS The PRIORITY population consisted of 11020 patients who underwent iso-
lated CABG (27.2% performed OP). The follow-up time ranged from 4 to 10 years.
Although unadjusted long-term survival was signiﬁcantly worst for OP CABG, the
adjustment did not conﬁrm OP CABG as a risk factor for mortality (hazard ratio ¼ 0.96,
p-value¼ 0.407). The incidence of postoperative PCI was signiﬁcantly higher in OP
than in the ON CABG group (2.64% vs 0.98%; p-value <0.0001). The signiﬁcantly
better cumulative incidence function of hospitalization for PCI at follow-up in the ON
CABG group was conﬁrmed even by the adjustment for confounding factors (ON
CABG adjusted hazard ratio ¼ 0.70; 95% CI¼ 0.62-0.80). Hence, ON CABG represents
an independent protective factor for recurrent PCI after CABG.
CONCLUSIONS This study demonstrated that the surgical technique used to perform
a CABG intervention does not affect mid-long-term mortality. Nonetheless, ON CABG
showed to be an independent risk factor for patients’ later PCI.CARDIOVASCULAR PHARMACOLOGY
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Anti-coagulant Therapy During Percutaneous Coronary Intervention: A Network
Meta-analysis Of Randomized Trials
Tilak Pasala,1 Rama Dilip Gajulapalli,1 Shari Bolen2
1Case Western Reserve University/MetroHealth, Cleveland, OH; 2Center for Health Care
Research and Policy, Case Western Reserve University School of Medicine, Cleveland,
OH
BACKGROUND Choosing the right anti-coagulant (AC) during percutaneous coronary
intervention (PCI) for the right patient that balances the bleeding risk with ischemic
efﬁcacy is an ongoing challenge. We did a network meta-analysis to compare the
currently used ACs for PCI.
METHODS We searched PubMed, The Cochrane Library, and relevant meeting ab-
stracts for randomized trials that compared unfractionated heparin (UFH), bivalir-
udin, and low molecular weight heparin (LMWH) with or without glycoprotein IIb/IIIa
inhibitor (GPI) for PCI. Endpoints (up to 30-day) included were: major bleeding (MB),
death, major adverse cardiac events (MACE), and stent thrombosis (ST).
RESULTS We analyzed 74 trials (n ¼ 73,760) allocated to 6 AC combinations
(Figure 1A). Compared to UFH, UFHþGPI, bivalirudin, LMWH, and LMWHþGPI were
associated with lower MACE (Figure 1B). The hierarchy for MACE (highest to lowest)
was LMWHþGPI, UFHþGPI, bivalirudinþGPI, LMWH, Bivalirudin and UFH. While
there was no statistical difference between ACs for death, LMWH was ranked the
highest and UFH the lowest (SUCRA values 72% and 28% respectively). Bivalirudin
was the safest AC (Figure 1C and 1D), and was associated with lower MB compared to
UFHþGPI (odds ratio (OR) 0.54, 95% conﬁdence interval (CI) 0.42-0.68) and UFH (OR
0.68, CI 0.51-0.90). However, ST was higher with bivalirudin compared to UFHþGPI
(OR 1.72, CI 1.10-2.67).
CONCLUSIONS LMWHþGPI and UFHþGPI are the most effective and bivalirudin the
safest AC for PCI. AC selection maybe tailored to patient’s risk proﬁle.
Table. Clinical outcomes upto 5-years
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Impact Of Renin-angiotensin-aldosterone System Inhibitors On 5-year Clinical
Outcomes in Patients with Signiﬁcant Coronary Artery Spasm; A Propensity
Score Matching Study
Se Yeon Choi,1 Seung-Woon Rha,2 Byoung Geol Choi,2 Sang-Ho Park,3 Woong Gil Choi,4
Soo Hyun Kim,5 Eun-Gyu Lee,6 Ji Young Park,7 Jihun Ahn,8 Sang Yeub Lee,9
Sang Min Kim,9 Min Woong Kim,10 Seong Gyu Yoon,1 Tae Hoon Ahn,11 Dong Joo Oh2
1Department of Medicine, Korea University Graduate School, Seoul, Korea, Republic of;
2Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea, Republic of;
3Cardiology Department, Soonchunhyang University Cheonan Hospital, Cheonan,
Korea, Republic of; 4Division of Cardiology, Konkuk University Chungju Hospital,
Chungju, Korea, Republic of; 5Division of Cardiology, Konkuk University Chungju
Hospital, chungju, Korea, Republic of; 6Cardiovascular Cencer, Andong Sungso
Hospital, Andong, Korea, Republic of; 7Cardiology Department, Eulji General Hospital,
Seoul, Korea, Republic of; 8Department of Internal Medicine, Soonchunhyang
University Gumi Hospital, Gumi, Korea, Republic of; 9Cardiovascular Center,
Chungbuk National University Hospital, Cheongju, Korea, Republic of; 10Department of
Cardiology, Hanyang University Medical Center, Hanmaeum Hospital, Changwon,
Korea, Republic of; 11Gachon University of Medicine and Science, Gil Hospital, Incheon,
Korea, Republic of
BACKGROUND It has been well known that a major cause of vasospastic angina is
endothelial dysfunction of the coronary artery. Also, renin-angiotensin-aldosterone
system (RAAS) is known to be closely associated with endothelial dysfunction.
However, there is no study for impact of RAAS inhibitor on long-term clinical out-
comes in vasospastic angina patients (pts).
METHODS A total of 3,349 consecutive pts without signiﬁcant coronary artery disease
(CAD) underwent acetylcholine (Ach) provocation test and diagnosed as CAS between
Nov. 2004 and May. 2014 were enrolled. Signiﬁcant CAS was deﬁned as > 70% of
narrowing by incremental intracoronary injection of 20, 50 and 100 mg into left cor-
onary artery. Pts were divided into two groups based on the treat of RAAS inhibitors
(the RAAS group: n¼666, the control group; n¼2683). To adjust potential con-
founders, a propensity score matched (PSM) analysis was performed using the logistic
regression model.
RESULTS After PSM analysis, 2 propensity-matched groups (1,143 pairs, n ¼ 2,286, C-
statistic¼0.845) were generated and the baseline characteristics of the two groups
were balanced. At 5 years, despite of similar incidence of individual hard endpoints
including mortality, myocardial infarction and revascularization, the RAAS inhibitors
group were signiﬁcantly associated with lower incidence of recurrent angina
requiring repeat coronary angiography than the control group (HR; 0.63, 95% C.I;
0.40-0.99, p¼0.048, Table and Figure).
CONCLUSIONS In our study, RAAS inhibitor was associated with reduced
incidence of recurrent angina in pts with vasospastic angina up to 5-year clinical
follow-up.CRT-138
Impact of Trimetazidine Treatment on 5-year Clinical Outcomes in Patients with
Signiﬁcant Coronary Artery Spasm; A Propensity Score Matching Study
Seung-Woon Rha,1 Byoung Geol Choi,2 Se Yeon Choi,1 Ji Young Park,3 Sang-Ho Park,4
Jihun Ahn,5 Woong Gil Choi,6 Soo Hyun Kim,6 Eun-Gyu Lee,7 Sang Yeub Lee,8
Sang Min Kim,8 Min Woong Kim,9 Seong Gyu Yoon,2 Tae Hoon Ahn,10 Dong Joo Oh1
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of; 5Department of Internal Medicine, Soonchunhyang University Gumi Hospital,
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BACKGROUND Trimetazidine (VastinanTM) is an anti-ischemic metabolic agent,
which improves myocardial glucose utilization through inhibition of fatty acid
metabolism, also known as fatty acid oxidation inhibitor. Trimetazidine usually
prescribed as a long-term treatment of angina pectoris. The aim of this study is
to investigate clinical impact of trimetazidine as an additional treatment of acetyl-
choline (Ach) induced coronary artery spasm (CAS) on clinical outcomes up to
ﬁve-years.
METHODS A total of 3,360 consecutive patients (pts) underwent Ach provocation
test and positive CAS pts were enrolled between Nov. 2004 and May. 2014. Sig-
niﬁcant CAS was deﬁned as > 70% of narrowing by incremental intracoronary in-
jection of 20, 50 and 100 mg into left coronary artery. Pts were divided into two
groups: the Trimetazidine group (DiltiazemþNitrateþTrimetazidine; n¼1,154), the
control group (DiltiazemþNitrateþPlacebo; n¼745). To adjust potential confounders,
a propensity score matched (PSM) analysis was performed using the logistic
regression model.
RESULTS After PSM analysis, 2 propensity-matched groups (659 pairs, n ¼1,318, C-
statistic¼0.695) were generated and the baseline characteristics of the two groups
were balanced. At 5 years, there were similar incidence of individual hard endpoints
including mortality, myocardial infarction, revascularization and recurrent angina
requiring repeat coronary angiography.
CONCLUSIONS In this study, despite the expected improvement if ischemic symp-
toms by anti-ischemic mechanisms, an additional treatment with Trimetazidine in
CAS pts was not associated with improving clinical outcomes up to ﬁve-years. To get a
ﬁnal conclusion, a large scale randomized trial would be needed.
Table. Clinical Outcomes up to 5-years after Propensity Score Matching
